30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 8
- 主要终点
- SIGH-ADS Score
研究概览
简要总结
The primary objective of this study is to evaluate the effect of light therapy using a narrow 467nm light compared to a 580nm light in subjects with Seasonal Affective Disorder (SAD). It is hypothesized that the 467nm light will improve the symptoms of SAD better than the 580nm light.
详细描述
Participants will be randomly assigned to receive either a 467nm light or a 580nm light. Participants will use the light every day for six weeks for 30 minutes. Multiple assessments and questionnaires will be given weekly to assess the efficacy of the treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females, ages 21-64
- •Able and willing to provide written informed consent
- •History of recurrent major depressive episodes with winter-type seasonal pattern by Diagnostic and Statistical Manual of the American Psychiatric Associated, 4th Ed. (DSM-IV) criteria (American Psychiatric Association, 1990), based on diagnostic interview utilizing the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (First et al., 2007)
- •*Bipolar I excluded for this study
- •SIGH-ADS score of ≥20
- •Use of the light device as instructed by the study clinician for at least 6 out of 7 days for the first two weeks of therapy and at least 5 out of 7 days for the remaining four weeks of therapy.
排除标准
- •Participation in a study of investigational or marketed drugs or devices during the 30-day period prior to the start of the study or during the study
- •Subjects who are medically complicated, medically unstable and/or have other severe diseases, as determined by the investigator.
- •Abnormal TSH level, (outside range of 0.3 to 5.0 mlU/L), as determined by the TSH levels blood test
- •History of concurrent psychiatric illness that would preclude compliance with the protocol and/or ability to complete the study safely
- •History or current diagnosis of Bipolar I Disorder
- •Variable psychiatric symptoms such as rapid cycling or severe premenstrual syndrome that could interfere with accurate assessment of the treatment effect
- •History of a medical condition that affects mood or produces hallmark symptoms of a mood disorder (i.e. hypothyroidism)
- •History of current or recent (within previous 12 months) alcohol, narcotic or other drug abuse by DSM-IV criteria
- •Positive urine drug screen at the Physical Screening
- •Active suicidal or homicidal ideation or plan, as determined by the investigator
- •Global Assessment of Functioning (GAF) <51 (see Appendix B)
- •Use of light therapy treatment within the previous 6 months or any history of goLITE use
- •Pregnant or lactating (will confirm absence of pregnancy with a urine or serum pregnancy test in females of childbearing potential during the Physical Screening. Additional pregnancy tests may be performed as per individual site requirements). Females of child-bearing potential must agree to use some form of birth control throughout the course
- •Current use or use within 2 months of antidepressants or mood stabilizing medications, even if taken for a non-psychiatric indication
- •Currently working night shift or rotating shift or other habitual alteration of the sleep/wake cycle
- •Planned travel outside of the state in which the trial is being conducted
- •Current use or use within the previous 1 month of photosensitizing medications (amiodarone, benoxaprofen, chlorpromazine, demeclocycline, fleroxacin, nalidixic acid, ofloxacin, piroxicam, porfimer, psoralens, quinidine, temoporfin) or remedies (St. John's wort, melatonin)
- •History of eye trauma or disease, retinopathy, and/or cataract of a level that would significantly affect transmission or processing of light through either eye
- •Ishihara score of <10 on the Ishihara Test for Color Deficiency
- •Use of medications, such as tetracycline or oral isoretinoin (Accutane), that would affect the safety of light exposure treatment or that causes complaints of eyestrain or abnormal tearing with computer use of up to 30 minutes at a time
研究组 & 干预措施
goLITE
light therapy using 467nm LED source, within 30 minutes of waking in the morning every day for 6 weeks
干预措施: goLITE (Device)
Control
light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
干预措施: Control (Device)
结局指标
主要结局
SIGH-ADS Score
时间窗: 6 weeks
A Structured Interview Guide for the Hamilton Depression Scale with Atypical Depression Supplement was utilized at baseline and after 6 weeks of treatment. The SIGH-ADS is designed for general use in depression research and clinical evaluation, regardless of seasonality.The SIGH-ADS rates the severity of depressive symptoms in terms of Hamilton's 17-item depression score and an 8-item atypical score. Combined this provides 25 items to provide the SIGH-ADS score. SIGH-ADS scores range from 0-79; higher values represent increased depression severity and worse outcome, the lower the score the less depressed the patient is. All participants that entered the study had to have a score of 20 or greater.
次要结局
- SIGH-ADS Score (Week 1 Thru 5)(weekly, from Week 1 through week 5)
- Q-LES-Q-SF(6 weeks)